B001
Phase 3Biologic
B001 is one of 26 biologic programs targeting Neuromyelitis Optica. It is currently in Phase 3.
2
Indications
3
Total Trials
2
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
19 competitors in Neuromyelitis Optica
#DrugCompanyPhaseTrials
1Cellcept
RocheApproved
Soliris
AstraZenecaApproved
UPLIZNA
HHorizon Therapeutics Ireland DAC
Approved
Imuran
LLegacy Health System
Approved
Novantrone
EMD SeronoApproved
Rayos
RRoxane Laboratories
Approved
Brukinsa
BBeOne Medicines
Approved
Cytoxan
BBaxter Healthcare Corporation
Approved
Mesnex
BBaxter Healthcare Corporation
Approved
Darzalex
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Neuromyelitis Optica1 trial
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
Recruiting·SShanghai Jiaolian Drug Research and Development Co., Ltd·Phase 2/3·NCT06413654·132 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for B001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details